alexa Flurbiprofen: A Potent Pain Reliever | OMICS International
ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Flurbiprofen: A Potent Pain Reliever

Maroof K1, Zafar F1, Ali H1 and Naveed S2*

1Faculty of Pharmacy, Ziauddin University, Karachi, Pakistan

2Jinnah University for Women, Karachi, Pakistan

*Corresponding Author:
Naveed S
Jinnah University for Women
Karachi, Pakistan
Tel: 0300-2621917
E-mail: [email protected]

Received Date: October 10, 2014; Accepted Date: December 30, 2014; Published Date: January 02, 2015

Citation: Maroof K, Zafar F, Ali H, Naveed S (2015) Flurbiprofen: A Potent Pain Reliever. J Bioequiv Availab 7:056-058. doi: 10.4172/jbb.1000214

Copyright: © 2015 Maroof K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Bioequivalence & Bioavailability


Flurbiprofen, a non-steroidal anti-inflammatory analgesic drug is a phenylalkanoic acid derivative. It is used in degenerative joint disease, rheumatoid arthritis, allied conditions and ankylosing spondylitis. In this review article we have compile its chemistry pharmacokinetic study, dose mode of action and its uses.


Flurbiprofen; Pharmacokinetics; Dose


Flurbiprofen, a non steroidal anti-inflammatory drug is a phenylalkanoic acid derivative (2-2-Fluoro-4-biphenyl 4-yl, propionic acid) having molecular weight 244.3 g/mol with molecular formula of C15H13FO2 [1-3] . Flurbiprofen is commercially available as a racemate blend of (+) Sand (-) R-enantiomers. The enanteomeric form of the drug has potentially developing role in the treatment of Alzheimer’s disease and metastatic prostate cancer with anti-inflammatory activity [4-5]. Davis et al in 2000 observed the significant stimulatory effects on intestinal permeability in rats followed single oral doses of Flurbiprofen as racemate and enantiomer [6] (Figure 1).


Figure 1: Structure of flurbiprofen.


Flurbiprofen completely absorbed after oral administration [7] with peak plasma levels occurring at 1 hour Plasma concentration is related to dosage in the range 15 to 150 mg and peak plasma concentration is about 12μg/ml after a 100 mg dose and is usually attained 1.5 to 3 hours after ingestion [8,9]. Flurbiprofen is 99% bound to human serum albumin [10,11]. Flurbiprofen undergoes rapid oxidative metabolism and is excreted primarily in the urine as both glucuronide and sulphate conjugates and approx 20% of drug eliminated unchanged [10,11]. There are no known active metabolites in humans and there is no evidence of dose dependent alterations of pharmacokinetics or of drug accumulation in plasma after multiple dose administration. The elimination half-life is about 3.5 hours during repeated doses [12]. Gastric emptying rate is found notably higher in fed state [13]. Flurbiprofen is a CYP2C9 substrate and modification of the Dose adjustments are recommended when given with inhibitor of CYP2C9 agents [14]. Flurbiprofen gastrointestinal tolerance is considered better than other NSAIDs i.e. indomethacin and aspirin, and comparable to naproxen and ibuprofen. It has shown no problematic or irreversible hepatotoxic, carcinogenic or teratogenic effects. Hypertensive and renal effects are probably similar to other NSAIDs.


150-200 mg dose is recommended daily. 300 mg is the maximum daily dose. Drug should administer with food to prevent stomach upset [15].

Mechanism of Action: (Rephrase)

Flurbiprofen inhibits the enzyme (cyclooxygenase I and cyclooxygenase II) the makes prostaglandins which results in the valuable reduction in the concentrations of prostaglandins [16].


Flurbiprofen tablets are used in the management of acute or longterm treatment of osteoarthritis, rheumatoid arthritis, joint stiffness and dysmenorrhea [17,18] gout, ankylosing spondylitis, periodontitis, reduction postoperative pain, propofol injection pain, and in initial treated pain induced from cancer,Topical ophthalmic flurbiprofen preparations are also used to prevent intraoperative miosis [19].

Dosage Forms

It is available as 50 mg and 100 mg tablets and also as 0.03% ophthalmic solution [20]. Micro and nano emulsions are also reported in literature.

Drug Interactions

Flurbiprofen is shown to interact with Quinolone antacids, Aetaminophen, Fluconazole, Dapsone and Insulin [21-27]. Significant increase in toxicities of warfarin (anticoagulants), Lithium, Methotrexate and Cyclosporine are reported with Flurbiprofen. Reduction in urinary volume, sodium, and potassium concentration is also reported with concomitant use of furosemide and Flurbiprofen.

Other Interactions

Grape and cranberry juice significantly alters the drug clearance while pomegranate and blurberry showed no pharmacokinetic interaction with flurbiprofen [28-32].

Side Effects

Serious effects are dose related including ulcerations, burning, cramps, nausea, gastritis. GI bleeding, and liver toxicity is also reported with long term use. Rare effects range from Rash, ringing in the ears to lightheadedness [28].


Risk of upper gastrointestinal ulcer, asthma, heart failure, hives, impaired kidney function patients associated with selective cyclooxygenase inhibitors.

Pregnancy and Lactation

Flurbiprofen is contraindicated in pregnancy and also nursing.


Overdose symptoms include nausea, stomach pain, vomiting, drowsiness, dizziness, less urination, problem breathing, and fainting [12,21].

Efficacy and Safety

Comparable efficacy of flurbiprofen is reported with acetaminophen and codeine in post-operative dental pain [33-37]. Flurbiprofen axetil used to decrease the pain at the site of injection. However, flurbiprofen efficacy in reducing pain sensation for propofol injection is inconsistent [38]. In another study flurbiprofen was also reported as efficient and suitable for topical application when compared with diclofenac sodium for treatment of soft-tissue rheumatism [39-47].


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • International Conference And Exhibition on Drug Safety & Pharmacovigilance
    August 29-30, 2018 Toronto, Canada
  • 6th European Biopharma Congress
    September 18-19, 2018 Amsterdam, Netherlands
  • 18th World Pharma Congress
    October 18-20, 2018 Warsaw, Poland

Article Usage

  • Total views: 12380
  • [From(publication date):
    January-2015 - Jul 20, 2018]
  • Breakdown by view type
  • HTML page views : 8541
  • PDF downloads : 3839

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version